TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Invex Therapeutics Ltd. ( (AU:IXC) ) is now available.
Invex Therapeutics Ltd has announced that its Annual General Meeting (AGM) will be held on November 25, 2025, with director nominations closing on October 7, 2025. This announcement is significant for stakeholders as it outlines the timeline for key governance activities, which could impact the company’s strategic direction and leadership.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company that focuses on repurposing the approved drug Exenatide for treating neurological conditions involving raised intracranial pressure, such as acute stroke and traumatic brain injury. The company has trademarked its repurposed Exenatide as Presendin™.
Average Trading Volume: 69,125
Technical Sentiment Signal: Buy
Current Market Cap: A$12.02M
See more insights into IXC stock on TipRanks’ Stock Analysis page.